Data from Study of Champions Oncology TumorGrafts to be Presented at European Society for Medical Oncology (ESMO) 2014 Congress

HACKENSACK, N.J., Sept. 24, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that data from a study of Champions' TumorGrafts® will be presented on Monday, Sept. 29, at the European Society for Medical Oncology (ESMO) 2014 Congress.

Presentation Details

Title: Patient-derived xenografts accurately capture clinical responses to treatment
Session: Trials and tribulations in oncology: Future approaches
Abstract: 1573PD
Time: 1 p.m. CEST
Location: Pamplona (Hall 4)

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

SOURCE Champions Oncology

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED